FIA
CRDL

FNY Investment Advisers’s Cardiol Therapeutics CRDL Stock Holding History

FNY Investment Advisers’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,305
Closed -$30K – 517
2023
Q3 		$30K Buy
+33,305
New +$31.8K 0.02% 276

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AXS Investments Port Chester, New York $248M AUM 15.95% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

FNY Investment Advisers's CRDL Position: Q4 2023 in Review

FNY Investment Advisers sold out of Cardiol Therapeutics (CRDL) in Q4 2023, closing a stake of 33,305 shares — an estimated $30K sold.

FNY Investment Advisers first reported a position in CRDL in Q3 2023 and held it in 1 quarter. The position peaked at $30K in Q3 2023. 32 funds tracked by Wall St. Rank hold CRDL as of Q4 2023.

  • FNY Investment Advisers reported no remaining Cardiol Therapeutics position as of Q4 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 33,305 Cardiol Therapeutics shares in Q4 2023, an estimated $30K.
  • FNY Investment Advisers first reported a position in Cardiol Therapeutics in Q3 2023 and held it in 1 quarter.
  • FNY Investment Advisers's Cardiol Therapeutics position peaked at $30K in Q3 2023.
  • 32 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2023.

Based on FNY Investment Advisers's 13F filing for Q4 2023, filed 12 Jan 2024.